Moreover, one study reported a higher incidence of thrombocytopenia when nivolumab was combined with GemCis.14 On the whole, PD-1 inhibitor (sintilimab) plus GemCis demonstrate promising antitumor activity without additional toxicity, which could be another effective first-line therapy and provide further evidence for combine therapy in patients with ICC. This evidence concerns the gene PDCD1 and Thrombocytopenia.